Targeting small airways to overcome resistance to therapy in asthma

迫切需要克服对目前严重哮喘治疗的抵抗。靶向炎症诱导的小气道收缩变化提供了一种替代策略。我们已经确定了一种新的支气管扩张剂，最大限度地放松收缩小鼠小气道时，目前的治疗是无效的。我们将在模拟人类哮喘关键特征的动物模型中证明其疗效，并确定改善控制不良哮喘结局的新方法。

There is a pressing need to overcome resistance to current therapies for severe asthma. Targetting inflammation-induced changes in small airway contraction offers an alternative strategy. We have identified a novel bronchodilator that relaxes maximally contracted mouse small airways when current treatment is ineffective. We will demonstrate its efficacy in animal models mimicking key features of human asthma, and define new ways to improve outcomes in poorly-controlled asthma.